Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanaoka, M.
Right arrow Articles by Ota, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanaoka, M.
Right arrow Articles by Ota, M.
(Chest. 2003;123:54-58.)
© 2003 American College of Chest Physicians

Polymorphisms of the Tyrosine Hydroxylase Gene in Subjects Susceptible to High-Altitude Pulmonary Edema*

Masayuki Hanaoka, MD; Yunden Droma, MD; Junichi Hotta, MD; Yukinori Matsuzawa, MD; Toshio Kobayashi, MD; Keishi Kubo, MD, FCCP and Masao Ota, PhD

* From the First Department of Medicine (Drs. Hanaoka, Droma, Hotta, Matsuzawa, Kobayashi, and Kubo) and Department of Legal Medicine (Dr. Ota), Shinshu University School of Medicine, Matsumoto, Japan.

Correspondence to: Masayuki Hanaoka, MD, First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan; e-mail: masayuki{at}hsp.md.shinshu-u.ac.jp

Study objectives: A blunted hypoxic ventilatory response (HVR) has been observed in some sufferers of high-altitude pulmonary edema (HAPE), and was proposed as a potential mechanism in its pathogenesis. Tyrosine hydroxylase (TH) is a rate-limiting enzyme in the carotid body responding to hypoxia to synthesize dopamine neurotransmitter to heighten ventilation. The association of constitutional susceptibility to HAPE regarding the blunted HVR aspect with polymorphisms of the TH gene was examined.

Design: A cross-sectional case control study.

Setting: Shinshu University Hospital, Matsumoto, Japan.

Participants: Forty-three subjects with a history of HAPE (HAPE group) and 51 healthy climbers without a history of HAPE (control group).

Measurements: The (TCAT)n tetranucleotide microsatellite repeats within intron 1 and Met81Val variant in exon 2 of the TH gene were investigated by polymerase chain reaction following either direct sequencing or restriction fragment length polymorphism. The HVR in 21 subjects among the HAPE group was also measured.

Results: No significant frequency differences could be found in terms of either of the two polymorphisms between the HAPE and control groups. Meanwhile, no relationships were observed between the HVR values of HAPE subjects and the individual alleles in both polymorphisms of the TH gene.

Conclusion: The genetic susceptibility of HAPE, specifically the blunted HVR in HAPE, is probably not associated with the mutations of the TH gene, implying that these two polymorphisms may not be a sufficient genetic marker for predicting a predisposition to the susceptibility to HAPE.

Key Words: carotid body • high-altitude pulmonary edema • hypoxic ventilatory response • polymorphism • tyrosine hydroxylase gene




This article has been cited by other articles:


Home page
ChestHome page
A. Ahsan, G. Mohd, T. Norboo, M. A. Baig, and M. A. Q. Pasha
Heterozygotes of NOS3 Polymorphisms Contribute to Reduced Nitrogen Oxides in High-Altitude Pulmonary Edema.
Chest, November 1, 2006; 130(5): 1511 - 1519.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.